Stockscreener 앱 받기
6.13
7.17%
0.41
전일 마감가:
$5.72
열려 있는:
$5.81
하루 거래량:
1.12M
Relative Volume:
1.46
시가총액:
$421.81M
수익:
$46.02M
순이익/손실:
$-70.80M
주가수익비율:
-3.3681
EPS:
-1.82
순현금흐름:
$-1.61M
1주 성능:
+5.51%
1개월 성능:
+10.45%
6개월 성능:
-33.15%
1년 성능:
-51.04%
1일 변동 폭
$5.73
$6.15
1주일 범위
$5.30
$6.29
52주 변동 폭
$3.91
$13.98
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
명칭
Eyepoint Pharmaceuticals Inc
전화
617-926-5000
주소
480 PLEASANT STREET, WATERTOWN, MA
EYPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
6.13 | 399.80M | 46.02M | -70.80M | -1.61M | -1.82 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-07 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-22 | 개시 | JP Morgan | Overweight |
| 2023-11-02 | 개시 | Mizuho | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-07-07 | 개시 | Chardan Capital Markets | Buy |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2021-01-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-04-06 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | 재개 | Laidlaw | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
모두보기
Eyepoint Pharmaceuticals Inc 주식(EYPT)의 최신 뉴스
EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus
EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus
EyePoint price target lowered to $26 from $30 at Mizuho - TipRanks
Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating - marketscreener.com
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Awards Major Stock Options Package: 7 New Hires Receive 136,700 Shares at $5.72 - Stock Titan
Mizuho cuts EyePoint Pharmaceuticals target to $26 By Investing.com - Investing.com India
Mizuho cuts EyePoint Pharmaceuticals target to $26 - Investing.com
Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
Balyasny Asset Management L.P. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Announces Participation at Upcoming Investor Conferences - Stock Titan
(EYPT) Technical Data - news.stocktradersdaily.com
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Yahoo Finance
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks
EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus
Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
EyePoint Pharmaceuticals Q1 2025 Earnings Preview - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint Pharmaceuticals
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - EyePoint Pharmaceuticals
A Peek at EyePoint Pharmaceuticals's Future Earnings - Nasdaq
EyePoint Pharmaceuticals stock sinks following clinical trial results By Investing.com - Investing.com Nigeria
(EYPT) Long Term Investment Analysis - news.stocktradersdaily.com
EyePoint Pharmaceuticals to Host Conference Call for Q1 2025 Financial Results on May 7 - Nasdaq
Pars Planitis Market Set to Grow Substantially Through 2032, - openPR.com
EyePoint (EYPT) Offers Stock Options as Inducement for New Hires | EYPT Stock News - GuruFocus
EyePoint Expands Team with Strategic Stock Options Package Worth $370K - Stock Titan
How the (EYPT) price action is used to our Advantage - news.stocktradersdaily.com
Nano Silicon Drug Delivery Platform Market to Witness Massive - openPR.com
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 7, 2025 - The Globe and Mail
EyePoint Pharmaceuticals' US$84m Market Cap Fall Books Insider Losses - simplywall.st
EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com Canada
Compliance - EyePoint Pharmaceuticals
Corporate Governance - EyePoint Pharmaceuticals
Working At Eyepoint - EyePoint Pharmaceuticals
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
Eyepoint Pharmaceuticals Inc (EYPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyepoint Pharmaceuticals Inc 주식 (EYPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
| Elston George | Chief Financial Officer |
Jan 06 '25 |
Option Exercise |
0.00 |
15,285 |
0 |
73,374 |
| Elston George | Chief Financial Officer |
Jan 05 '25 |
Option Exercise |
0.00 |
15,000 |
0 |
63,356 |
| Lurker Nancy | Director |
Jan 06 '25 |
Option Exercise |
0.00 |
75,134 |
0 |
185,436 |
| Lurker Nancy | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
12,667 |
0 |
110,302 |
| Landis John B. | Director |
Jan 05 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
21,400 |
| Duker Jay S. | President and CEO |
Jan 06 '25 |
Option Exercise |
0.00 |
20,794 |
0 |
78,814 |
1.54%
7.58%
자본화:
|
볼륨(24시간):